Blog
Published February 18, 2022
Executive Summary
A new pan-European Health Technology Assessment (HTA) regulation that will redefine the processes for the evaluation of new medicines in the EU entered into force in January 2022
Although it will not become fully active until 2025, the new regulation will require EU member states to give “due consideration” to joint clinical assessment (JCA) reports and provide feedback to the European Commission
These new JCAs will only focus on the clinical domain of HTAs and thus they will…
Read Now
Briefs
What is keeping commercial data leaders in emerging life sciences companies up at night as they bring their technology to life in preparation for launch? What are the biggest concerns when considering changes to an existing infrastructure? Trinity Life Sciences has partnered with many first launch and emerging companies for decades to find solutions to their biggest technology challenges.
In this Advisory Brief, we pause to reflect upon some of the common missteps we’ve seen companies take when deploying their…
Read Now
Webinars
Available On Demand
Life science Competitive Intelligence (CI) is growing in importance and impact. From innovation in technology to the number of products launching to the more connected global marketplace, CI teams are wrestling with the needs of an evolving function. With more data coming at CI teams faster, organizations need to adapt and optimize or be left behind. Pulling from the initial findings of a recent study, Trinity’s team of CI-focused experts share insights and commentary on the opportunities and challenges facing…
Watch Now
Blog
Published February 2, 2022
The National Institute for Health and Care Excellence (NICE) will mark the start of 2022 by implementing changes to health technology assessments (HTAs), demonstrating adaptability of regulatory bodies as medical technologies continue to evolve. The final HTA changes aim to provide earlier and more equitable access to treatments as well as display increased flexibility in the evaluation of new health technologies. As part of NICE’s plan to modernize healthcare, the changes will apply to both digital therapeutics as well as…
Read Now
Webinars
Available On Demand
Life science forecasters support complex analytical needs, all while grappling with ever-changing assumptions and datastreams. Working in Excel is often one of the few constants, but the comfort of working with a familiar tool frequently becomes a trade-off in functionality as forecasters pursue easy consolidation and communication, greater version control and intuitive scenario planning.
Trinity’s forecasting team has focused on life sciences forecasting and modeling projects for 25 years—and that breadth and depth of experience drove the creation of Trinity…
Watch Now
White Papers
Over the past few years, there has been a spotlight on gender representation in leadership in a wide range of industries. Women are underrepresented in healthcare and biotech companies, despite evidence showing that companies that don’t have equitable representation perform worse compared to those that do.
While this is recognized, there is a lack of understanding about the scope of the problem within life sciences consulting. In general, there is a lack of transparency on these issues, with a resulting…
Read Now
Briefs
Throughout 2021, we’ve continued to face historic, massive challenges related to the ongoing global pandemic. Life sciences enterprises, and essentially all industries, grappled with decisions large and small. Priorities for Commercial and Medical Affairs organizations in the life sciences industry shifted as you worked feverishly to evolve virtual and digital channels to engage with customers as well as internal teams. Developing capabilities and skills in new ways of working came to the forefront, along with new challenges related to vaccinations…
Read Now
Blog
Published December 6, 2021
Executive Summary
The National Institute for Health and Care Excellence (NICE) is the major reimbursement body and pathway to achieving market access in England, although products that have not been evaluated by NICE or have received a negative NICE outcome can still achieve local access through CCGs (Clinical Commissioning Groups)
In 2017, NHS England announced deals facilitating patient access to two innovative treatments (KADCYLA and STRENSIQ). KADCYLA’s previous negative NICE recommendation in HER2+ breast cancer and strong patient advocacy from…
Read Now
White Papers
Patient Finding is an innovative tool to improve customer targeting that can be implemented fairly quickly, without a lot of organizational disruption, retraining, or complex data integration. It is a worthwhile addition to your portfolio of targeting methods.
For appropriate brands, Patient Finding can provide a significant competitive advantage. As it becomes more widely used by the pharma industry, late adopters may find themselves at a competitive disadvantage.
Complete the form below to access “Why you should consider Patient Finding…
Read Now
Blog
Published November 12, 2021
Executive Summary
Given the growing number of digital health technologies available, there is a wide range of frameworks that outline key requirements to support decision-makers with the value assessment of digital health solutions
Understanding how requirements differ based on the country and organization that develops the framework is key to prepare the successful global launch of a digital health technology
Clinical evidence that demonstrates an improvement in the state of health or quality of life should be taken into consideration…
Read Now
